Additional seminal studies have sought to more precisely quantify LSC frequency through limiting dilution experiments in immunodeficient mice; these studies highlighted the diversity of AML immunophenotypes in primary patient samples and revealed that LSC activity was not restricted to the CD34+CD38- cells, nor even to those lacking lineage markers [15]. The gene discussed is CD38; the disease is acute myeloid leukemia.